A Look At Kodiak Sciences (KOD) Valuation After Zenkuda GLOW2 Phase 3 Success And BLA Plans

Simply Wall St.11:23

Kodiak Sciences (KOD) is back in focus after reporting that its GLOW2 Phase 3 study of Zenkuda in diabetic retinopathy met key efficacy and safety endpoints, supporting a multi-indication, BLA-ready ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624566883?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-01 11:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624566883","market":"nz","top_or_hot":-1,"title":"A Look At Kodiak Sciences (KOD) Valuation After Zenkuda GLOW2 Phase 3 Success And BLA Plans","media":"Simply Wall St.","content":"<div>\n<p>Kodiak Sciences (KOD) is back in focus after reporting that its GLOW2 Phase 3 study of Zenkuda in diabetic retinopathy met key efficacy and safety endpoints, supporting a multi-indication, BLA-ready ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/a-look-at-kodiak-sciences-kod-valuation-after-zenkuda-glow2\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Kodiak Sciences (KOD) Valuation After Zenkuda GLOW2 Phase 3 Success And BLA Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Kodiak Sciences (KOD) Valuation After Zenkuda GLOW2 Phase 3 Success And BLA Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-01 11:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/a-look-at-kodiak-sciences-kod-valuation-after-zenkuda-glow2><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kodiak Sciences (KOD) is back in focus after reporting that its GLOW2 Phase 3 study of Zenkuda in diabetic retinopathy met key efficacy and safety endpoints, supporting a multi-indication, BLA-ready ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/a-look-at-kodiak-sciences-kod-valuation-after-zenkuda-glow2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/a-look-at-kodiak-sciences-kod-valuation-after-zenkuda-glow2","article_id":"2624566883","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-kod/kodiak-sciences/news/a-look-at-kodiak-sciences-kod-valuation-after-zenkuda-glow2","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624566883","pubTimestamp":1775013807,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Kodiak Sciences (KOD) is back in focus after reporting that its GLOW2 Phase 3 study of Zenkuda in diabetic retinopathy met key efficacy and safety endpoints, supporting a multi-indication, BLA-ready profile.\nSee our latest analysis for Kodiak Sciences.\nThe Zenkuda update arrives alongside sharp recent moves in the stock, with a 74.46% 7 day share price return and a 42.24% 30 day share price return. The 1 year total shareholder return is very large, suggesting momentum has picked up sharply...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","KOD":"Kodiak Sciences Inc.","BK4139":"生物科技"},"translate_title":"Zenkuda GLOW2 3期成功和BLA计划后Kodiak Sciences(KOD)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"KOD":1.5},"content_text":"Kodiak Sciences (KOD) is back in focus after reporting that its GLOW2 Phase 3 study of Zenkuda in diabetic retinopathy met key efficacy and safety endpoints, supporting a multi-indication, BLA-ready profile. See our latest analysis for Kodiak Sciences. The Zenkuda update arrives alongside sharp recent moves in the stock, with a 74.46% 7 day share price return and a 42.24% 30 day share price return. The 1 year total shareholder return is very large, suggesting momentum has picked up sharply around Kodiak Sciences. If this kind of clinical news has your attention, it could be a good time to see what else is moving in ophthalmology and biotech by checking a focused healthcare AI stock screener such as 34 healthcare AI stocks. With Zenkuda now described as BLA ready and Kodiak Sciences still loss making, the rally raises a key question for you: is this surge leaving meaningful upside on the table, or is the market already pricing in future growth? AdvertisementDCF Signals Versus Market Price: How Wide Is The Gap? According to the SWS DCF model, Kodiak Sciences has an estimated future cash flow value of $356.43, compared with the recent share price of $38.12. This implies a large gap between modeled value and where the market is currently trading. The DCF model works by estimating all the cash Kodiak Sciences could generate in the future, then discounting those projected cash flows back to today using a required rate of return. The result is a single present value figure that can be compared directly with the share price, providing a framework for assessing how generously or cautiously the market is pricing those future cash flows. For a clinical stage biotech with no revenue and a net loss of $217.34m, this type of model is especially sensitive to assumptions about trial success, timing of potential approvals, and eventual commercial uptake. Those inputs are hard to pin down, which is why even a very large DCF upside can coexist with high uncertainty, analyst disagreement, and a volatile share price. Look into how the SWS DCF model arrives at its fair value. Result: DCF Fair value of $356.43 (UNDERVALUED) However, the company is still loss making, with net income of $217.336m in the red and a market cap of about $2.36b that already reflects strong expectations. Find out about the key risks to this Kodiak Sciences narrative. Another View: Market Ratios Point The Other Way While the SWS DCF model suggests a large gap between price and future cash flow value, the P/B ratio paints a very different picture. Kodiak Sciences trades at about 99.7x book value, compared with roughly 3x for peers and 2.1x for the wider US biotech group, which signals a high bar for expectations. This kind of premium can reward you if the story keeps improving, but it also leaves less room for error if clinical or funding setbacks appear. With such a wide spread between DCF upside and rich balance sheet pricing, which signal do you trust more right now? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:KOD P/B Ratio as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kodiak Sciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 58 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Sentiment appears mixed, with significant potential from Zenkuda balanced against a high valuation and meaningful execution risks. It may be sensible to act promptly, review the data directly, and consider both the potential benefits and the vulnerabilities by checking the 1 key reward and 4 important warning signs Looking for more investment ideas? If Kodiak Sciences has sharpened your focus, do not stop here. Broaden your watchlist with stocks that match clear, disciplined criteria instead of chasing headlines.  Spot potential turnaround names early by scanning 31 elite penny stocks with strong financials where solid financials help separate stories from speculation. Zero in on quality at a reasonable price by using the 58 high quality undervalued stocks to find companies with strong fundamentals that may not yet be fully appreciated. Strengthen the defensive side of your portfolio by checking the 64 resilient stocks with low risk scores for businesses showing resilient risk profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Kodiak Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624566883","isCrawlerRequest":true}